Miremont-Salamé G - Search Results

1

[Hospitalizations after substance use during the COVID-19 pandemic].

Dumoulin C, Ong N, Ramaroson H, Letinier L, Miremont-Salamé G, Gilleron V, Daveluy A, Perino J. Dumoulin C, et al. Among authors: miremont salame g. Therapie. 2023 May-Jun;78(3):334-338. doi: 10.1016/j.therap.2022.06.003. Epub 2022 Jun 30. Therapie. 2023. PMID: 35908997 Free PMC article. French. No abstract available.

2

Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration.

Smith CJ, Ryom L, Weber R, Morlat P, Pradier C, Reiss P, Kowalska JD, de Wit S, Law M, el Sadr W, Kirk O, Friis-Moller N, Monforte Ad, Phillips AN, Sabin CA, Lundgren JD; D:A:D Study Group. Smith CJ, et al. Lancet. 2014 Jul 19;384(9939):241-8. doi: 10.1016/S0140-6736(14)60604-8. Lancet. 2014. PMID: 25042234 Free article.

3

[Selective serotonin reuptake inhibitors and acne].

Daveluy A, de Bazignan AD, Thiessard F, Miremont-Salamé G, Moore N, Haramburu F; Centres Régionaux de Pharmacovigilance. Daveluy A, et al. Therapie. 2006 Jan-Feb;61(1):71-2. doi: 10.2515/therapie:2006004. Therapie. 2006. PMID: 16792157 French. No abstract available.

4

[Contact dermatitis caused by acetazolamide under occlusion].

Daveluy A, Vial T, Marty L, Miremont-Salamé G, Moore N, Haramburu F. Daveluy A, et al. Presse Med. 2007 Dec;36(12 Pt 1):1756-8. doi: 10.1016/j.lpm.2007.05.020. Epub 2007 Jun 18. Presse Med. 2007. PMID: 17574381 French.

5

Effect of date of drug marketing on disproportionality measures in pharmacovigilance: the example of suicide with SSRIs using data from the UK MHRA.

Pariente A, Daveluy A, Laribière-Bénard A, Miremont-Salame G, Begaud B, Moore N. Pariente A, et al. Drug Saf. 2009;32(5):441-7. doi: 10.2165/00002018-200932050-00007. Drug Saf. 2009. PMID: 19419238

6

Medicine or ecstasy? The importance of the logo.

Daveluy A, Miremont-Salamé G, Rahis AC, Delile JM, Bégaud B, Gachie JP, Haramburu F. Daveluy A, et al. Fundam Clin Pharmacol. 2010 Apr;24(2):233-7. doi: 10.1111/j.1472-8206.2009.00740.x. Epub 2009 Sep 16. Fundam Clin Pharmacol. 2010. PMID: 19758334

7

Fluindione and drug reaction with eosinophilia and systemic symptoms: an unrecognised adverse effect?

Daveluy A, Milpied B, Barbaud A, Lebrun-Vignes B, Gouraud A, Laroche ML, Ciobanu E, Bégaud B, Moore N, Miremont-Salamé G, Haramburu F; French Pharmacovigilance Centres Network and The Toxidermia Group of the French Society of Dermatology. Daveluy A, et al. Eur J Clin Pharmacol. 2012 Jan;68(1):101-5. doi: 10.1007/s00228-011-1101-9. Epub 2011 Jul 27. Eur J Clin Pharmacol. 2012. PMID: 21792562

8

Identification of abuse and dependence cases through a hospital database.

Daveluy A, Miremont-Salamé G, Kostrzewa A, Couret A, Lacoin L, Lecomte C, Moore N, Gilleron V, Haramburu F. Daveluy A, et al. Pharmacoepidemiol Drug Saf. 2012 Dec;21(12):1344-9. doi: 10.1002/pds.3369. Epub 2012 Oct 30. Pharmacoepidemiol Drug Saf. 2012. PMID: 23111820

9

Probable interaction between an oral vitamin K antagonist and turmeric (Curcuma longa).

Daveluy A, Géniaux H, Thibaud L, Mallaret M, Miremont-Salamé G, Haramburu F. Daveluy A, et al. Therapie. 2014 Nov-Dec;69(6):519-20. doi: 10.2515/therapie/2014062. Epub 2014 Sep 18. Therapie. 2014. PMID: 25230280

10

Statins in pregnancy: new safety data are reassuring, but suspension of treatment is still advisable.

Haramburu F, Daveluy A, Miremont-Salamé G. Haramburu F, et al. BMJ. 2015 Mar 17;350:h1484. doi: 10.1136/bmj.h1484. BMJ. 2015. PMID: 25784692 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

101 results

Search Page